Direct switch from levodopa/benserazide or levodopa/carbidopa to levodopa/carbidopa/entacapone in Parkinson's disease patients with wearing-off : efficacy, safety and feasibility--an open-label, 6-week study
(2010) In Journal of Neural Transmission 117(3). p.333-342- Abstract
The study objective was to assess the efficacy, safety and feasibility of switching from levodopa/benserazide (LB) or levodopa/carbidopa (LC) to levodopa/carbidopa/entacapone (LCE) in Parkinson's disease (PD) patients with wearing-off. This was a multicenter, open-label, 6-week study; the primary outcome was success rate based on the patient-assessed Clinical Global Impression of Change (P-CGI-C). Secondary outcomes included investigator-assessed CGI-C (I-CGI-C), change from baseline in Unified Parkinson's Disease Rating Scale (UPDRS), motor/non-motor wearing-off symptoms and quality of life-visual analog scale (QoL-VAS). After switching to LCE, 77% of patients reported an 'improvement' (p < 0.0001 vs. patients reporting 'no change... (More)
The study objective was to assess the efficacy, safety and feasibility of switching from levodopa/benserazide (LB) or levodopa/carbidopa (LC) to levodopa/carbidopa/entacapone (LCE) in Parkinson's disease (PD) patients with wearing-off. This was a multicenter, open-label, 6-week study; the primary outcome was success rate based on the patient-assessed Clinical Global Impression of Change (P-CGI-C). Secondary outcomes included investigator-assessed CGI-C (I-CGI-C), change from baseline in Unified Parkinson's Disease Rating Scale (UPDRS), motor/non-motor wearing-off symptoms and quality of life-visual analog scale (QoL-VAS). After switching to LCE, 77% of patients reported an 'improvement' (p < 0.0001 vs. patients reporting 'no change or worsening'). Significant improvements were seen in I-CGI-C, UPDRS and QoL-VAS, regardless of prior therapy. Oral levodopa dosing was increased in 28% of patients; the primary outcome remained significant when these patients were excluded. The data suggest that switching from LB/LC to LCE provided a significant benefit in PD patients with wearing-off.
(Less)
- author
- Eggert, Karla ; Skogar, Orjan LU ; Amar, Khaled ; Luotonen, Liisa ; Kuoppamäki, Mikko ; Leinonen, Mika ; Nissinen, Helena and Oertel, Wolfgang
- publishing date
- 2010-03
- type
- Contribution to journal
- publication status
- published
- keywords
- Aged, Antiparkinson Agents/administration & dosage, Benserazide/administration & dosage, Carbidopa/administration & dosage, Catechols/administration & dosage, Drug-Related Side Effects and Adverse Reactions, Dyskinesias/drug therapy, Feasibility Studies, Female, Humans, Levodopa/administration & dosage, Male, Nitriles/administration & dosage, Parkinson Disease/drug therapy, Severity of Illness Index, Surveys and Questionnaires, Treatment Outcome
- in
- Journal of Neural Transmission
- volume
- 117
- issue
- 3
- pages
- 333 - 342
- publisher
- Springer
- external identifiers
-
- scopus:77952430396
- pmid:20013007
- ISSN
- 0300-9564
- DOI
- 10.1007/s00702-009-0344-4
- language
- English
- LU publication?
- no
- id
- a1799725-b78a-41c3-8c9d-7d343e14358e
- date added to LUP
- 2024-05-08 15:06:06
- date last changed
- 2024-06-06 11:57:57
@article{a1799725-b78a-41c3-8c9d-7d343e14358e, abstract = {{<p>The study objective was to assess the efficacy, safety and feasibility of switching from levodopa/benserazide (LB) or levodopa/carbidopa (LC) to levodopa/carbidopa/entacapone (LCE) in Parkinson's disease (PD) patients with wearing-off. This was a multicenter, open-label, 6-week study; the primary outcome was success rate based on the patient-assessed Clinical Global Impression of Change (P-CGI-C). Secondary outcomes included investigator-assessed CGI-C (I-CGI-C), change from baseline in Unified Parkinson's Disease Rating Scale (UPDRS), motor/non-motor wearing-off symptoms and quality of life-visual analog scale (QoL-VAS). After switching to LCE, 77% of patients reported an 'improvement' (p < 0.0001 vs. patients reporting 'no change or worsening'). Significant improvements were seen in I-CGI-C, UPDRS and QoL-VAS, regardless of prior therapy. Oral levodopa dosing was increased in 28% of patients; the primary outcome remained significant when these patients were excluded. The data suggest that switching from LB/LC to LCE provided a significant benefit in PD patients with wearing-off.</p>}}, author = {{Eggert, Karla and Skogar, Orjan and Amar, Khaled and Luotonen, Liisa and Kuoppamäki, Mikko and Leinonen, Mika and Nissinen, Helena and Oertel, Wolfgang}}, issn = {{0300-9564}}, keywords = {{Aged; Antiparkinson Agents/administration & dosage; Benserazide/administration & dosage; Carbidopa/administration & dosage; Catechols/administration & dosage; Drug-Related Side Effects and Adverse Reactions; Dyskinesias/drug therapy; Feasibility Studies; Female; Humans; Levodopa/administration & dosage; Male; Nitriles/administration & dosage; Parkinson Disease/drug therapy; Severity of Illness Index; Surveys and Questionnaires; Treatment Outcome}}, language = {{eng}}, number = {{3}}, pages = {{333--342}}, publisher = {{Springer}}, series = {{Journal of Neural Transmission}}, title = {{Direct switch from levodopa/benserazide or levodopa/carbidopa to levodopa/carbidopa/entacapone in Parkinson's disease patients with wearing-off : efficacy, safety and feasibility--an open-label, 6-week study}}, url = {{http://dx.doi.org/10.1007/s00702-009-0344-4}}, doi = {{10.1007/s00702-009-0344-4}}, volume = {{117}}, year = {{2010}}, }